ALK and non-small cell lung carcinoma: Dysgeusia is also a common toxicity reported with crizotinib, a multitargeted TKI of anaplastic lymphoma kinase (ALK), mesenchymal-to-epithelial transition (MET) protein, and ROS proto-oncogene 1 (ROS1) used for the treatment of ALK-positive non-small cell lung cancer (NSCLC).